Company Filing History:
Years Active: 2023
Title: Anna Haydn: Innovator in Modified IL-2 Polypeptides
Introduction
Anna Haydn is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of biotechnology, particularly in the development of modified IL-2 polypeptides. Her work focuses on innovative treatments for diseases, including cancer.
Latest Patents
Anna Haydn holds a patent for "Modified IL-2 polypeptides and uses thereof." This patent relates to modified IL-2 polypeptides, compositions that include these polypeptides, and methods for their production and application. The invention emphasizes the treatment of cancer using these modified IL-2 polypeptides, which exhibit preferential binding characteristics to the IL-2 receptor βγ complex over the IL-2 receptor αβγ complex. The molecular weight distribution of these polypeptides is designed to be monodispersed, enhancing their therapeutic potential.
Career Highlights
Anna is associated with Bright Peak Therapeutics AG, where she continues to advance her research and development efforts. Her innovative approach has positioned her as a key figure in the biotechnology sector, contributing to the understanding and treatment of complex diseases.
Collaborations
Anna collaborates with notable professionals in her field, including Vijaya Raghavan Pattabiraman and Roberto Iacone. These partnerships enhance her research capabilities and broaden the impact of her inventions.
Conclusion
Anna Haydn is a trailblazer in the field of modified IL-2 polypeptides, with a focus on cancer treatment. Her innovative work and collaborations continue to push the boundaries of biotechnology, making significant strides in medical research and applications.